Campbell Bunce Selected Research

vatreptacog alfa

10/2019

Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Campbell Bunce Research Topics

Disease

1	Hemophilia A (Haemophilia) 10/2019
1	Human Influenza (Influenza) 01/2017
1	Inflammation (Inflammations) 01/2006
1	Infections 01/2006
1	Mastocytosis 01/2006
1	Vascular System Injuries 06/2004
1	Hyperplasia 06/2004

Drug/Important Bio-Agent (IBA)

2	Proteins (Proteins, Gene)FDA Link 10/2019 - 01/2006
1	AntibodiesIBA 10/2019
1	recombinant FVIIa (rFVIIa)FDA Link 10/2019
1	vatreptacog alfaIBA 10/2019
1	Pharmaceutical PreparationsIBA 10/2019
1	Factor IX (Coagulation Factor IX)FDA LinkGeneric 10/2019
1	Factor VII (Proconvertin)IBA 10/2019
1	Factor VIII (Coagulation Factor VIII)IBA 10/2019
1	VaccinesIBA 01/2017
1	InterleukinsIBA 01/2006
1	CytokinesIBA 01/2006
1	Carrier Proteins (Binding Protein)IBA 06/2004
1	ChemokinesIBA 06/2004
1	CXC ChemokinesIBA 06/2004

Therapy/Procedure

1	Ligation 01/2006